-SKYCellflu, the world’s first cell culture-based influenza vaccine obtaining WHO’s PQ, will be deli...

-SK bioscience makes a strategic equity investment in Novavax to respond to the endemic situation an...

SK bioscience donated to support the local community where L House, SK bioscience’s vaccine manufact...

SK bioscience identified 11 top-priority issues by adopting Double Materiality Assessment. Company e...

-Jaeyong Ahn, the CEO of SK bioscience, virtually joined the WHO workshop with representatives of gl...

SK bioscience and the Government Pharmaceutical Organization agreed to establish a pandemic response...

-The 21-valent pneumococcal conjugate vaccine candidate, GBP410 (also known as SP0202), demonstrates...

SK bioscience will collaborate with one of the world’s leading biomedical research institutes, the P...

- In a Phase III trial, the vaccine demonstrated neutralizing antibody responses against SARS-CoV-2 ...

The MHRA’s Marketing Authorization for SK bioscience COVID-19 vaccine is valid in the United Kingdom...

Jaeyong Ahn, CEO of SK bioscience presented the ‘Glocalization’ project to secure the vaccine access...

The vaccine will be manufactured at L HOUSE, SK bioscience’s vaccine manufacturing plant.“We will co...